Celsion Corporation to Hold Second Quarter 2017 Financial Results Conference Call on Tuesday, August 15, 2017
August 08, 2017 09:00 ET
|
Celsion Corporation
LAWRENCEVILLE, N.J., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN) announced today that the Company will host a conference call to discuss financial results for the quarter...
Data Monitoring Committee Completes Mid-Study Review of Celsion’s Phase III ThermoDox® OPTIMA Study in Primary Liver Cancer
August 07, 2017 08:00 ET
|
Celsion Corporation
OPTIMA Study at Over 60% Patient Enrollment, DMC Provides Unanimous Recommendation to Continue Celsion Summarizes Regulatory Strategy for ThermoDox® LAWRENCEVILLE, N.J., Aug. 07, 2017 (GLOBE...
Celsion Corporation to Delist from the Tel Aviv Stock Exchange
August 04, 2017 18:35 ET
|
Celsion Corporation
Limited TASE Trading Activity Does Not Warrant Listing Shares to Continue Listing and Trading on the NASDAQ Capital Market LAWRENCEVILLE, N.J., Aug. 04, 2017 (GLOBE NEWSWIRE) -- Celsion...
Celsion Announces Latest Translational Data from the OVATION Study in Newly Diagnosed Advanced Ovarian Cancer Patients
August 02, 2017 08:00 ET
|
Celsion Corporation
LAWRENCEVILLE, N.J., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN) today announced findings from the translational research data from its Phase Ib dose escalating clinical...
Celsion Corporation Announces $5 Million Registered Direct Offering
July 06, 2017 09:15 ET
|
Celsion Corporation
LAWRENCEVILLE, N.J., July 06, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (the “Company”) (NASDAQ:CLSN) today announced that it has entered into definitive agreements with several institutional...
Celsion Announces Completion of OVATION Study and Provides Update on its Immunotherapy Trial in Advanced Stage III and IV Ovarian Cancer
July 05, 2017 08:00 ET
|
Celsion Corporation
86% Objective Response Rate (ORR) in Phase IB Dose Escalating Study 100% ORR and 100% R0 (Margin Negative) Surgical Resection Rate at Highest Dose Cohort Increased Ratio of CD8+ Cells to...
Celsion Corporation Announces Cancellation of Registered Direct Offering
June 22, 2017 15:00 ET
|
Celsion Corporation
LAWRENCEVILLE, N.J., June 22, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (the “Company”) (NASDAQ:CLSN) today announced that it has cancelled the registered direct offering of common stock...
Celsion Corporation Announces $5.4 Million Registered Direct Offering
June 19, 2017 09:15 ET
|
Celsion Corporation
LAWRENCEVILLE, N.J., June 19, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (the “Company”) (NASDAQ:CLSN) today announced that it has entered into definitive agreements with several institutional...
Celsion Corporation Regains Compliance with NASDAQ Listing Requirements
June 14, 2017 08:00 ET
|
Celsion Corporation
LAWRENCEVILLE, N.J., June 14, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an oncology drug development company, today announced that it received notice from The NASDAQ Stock Market...
Celsion Announces Presentation of OVATION Study Findings at the ASCO 2017 Annual Meeting
June 05, 2017 08:00 ET
|
Celsion Corporation
100% disease control rate and 86% objective response rate reported All patients at the highest dose demonstrated an objective response rate - partial (80%) or complete (20%) response rate...